Nils Schroter
Overview
Explore the profile of Nils Schroter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rau A, Philipsen L, Frings L, Muller-Glaw P, Reisert M, Mast H, et al.
Brain
. 2025 Feb;
PMID: 39985450
Cognitive impairment is a major contributor to the burden in Parkinson's disease and dementia with Lewy bodies, both of which make up the Lewy body disease spectrum, with dementia affecting...
2.
Rau A, Reisert M, Urbach H, Weiller C, Schroter N, Hosp J
Neuroimage
. 2024 Oct;
302:120898.
PMID: 39442898
No abstract available.
3.
Frommer M, Walz I, Aiple F, Schroter N, Maurer C, Rijntjes M, et al.
Brain Sci
. 2024 Jul;
14(7).
PMID: 39061408
Delayed therapy escape (DTE) is frequent after thalamic deep brain stimulation for essential tremor, leading to reduced quality of life, often with ataxic symptoms, and early recognition is challenging. Our...
4.
Sajonz B, Brugger T, Reisert M, Buchsel M, Schroter N, Rau A, et al.
Brain Sci
. 2024 Jun;
14(6).
PMID: 38928612
Cerebral intraparenchymal hemorrhage due to electrode implantation (CIPHEI) is a rare but serious complication of deep brain stimulation (DBS) surgery. This study retrospectively investigated a large single-center cohort of DBS...
5.
Brumberg J, Blazhenets G, Buhler S, Fostitsch J, Rijntjes M, Ma Y, et al.
Ann Neurol
. 2024 Jun;
96(3):539-550.
PMID: 38888141
Objective: Patients with Lewy body diseases have an increased risk of dementia, which is a significant predictor for survival. Posterior cortical hypometabolism on [F]fluorodeoxyglucose positron emission tomography (PET) precedes the...
6.
Hosp J, Reisert M, Dressing A, Gotz V, Kellner E, Mast H, et al.
Nat Commun
. 2024 May;
15(1):4256.
PMID: 38762609
After contracting COVID-19, a substantial number of individuals develop a Post-COVID-Condition, marked by neurologic symptoms such as cognitive deficits, olfactory dysfunction, and fatigue. Despite this, biomarkers and pathophysiological understandings of...
7.
Hermann M, Schroter N, Rau A, Reisert M, Jarc N, Rijntjes M, et al.
Neuroimage Clin
. 2024 Apr;
42:103607.
PMID: 38643635
Background: Nigrostriatal microstructural integrity has been suggested as a biomarker for levodopa response in Parkinson's disease (PD), which is a strong predictor for motor response to deep brain stimulation (DBS)...
8.
Schroter N, Sajonz B, Jost W, Rijntjes M, Coenen V, Groppa S
J Neural Transm (Vienna)
. 2024 Apr;
131(11):1285-1293.
PMID: 38613674
Device aided therapies (DAT) comprising the intrajejunal administration of levodopa/carbidopa intestinal gel (LCIG) and levodopa/carbidopa/entacapone intestinal gel (LECIG), the continuous subcutaneous application of foslevodopa/foscarbidopa or apomorphine infusion (CSAI) and deep...
9.
Sajonz B, Frommer M, Reisert M, Blazhenets G, Schroter N, Rau A, et al.
Neuroimage Clin
. 2024 Feb;
41:103576.
PMID: 38367597
Background: Thalamic deep brain stimulation (DBS) is an efficacious treatment for drug-resistant essential tremor (ET) and the dentato-rubro-thalamic tract (DRT) constitutes an important target structure. However, up to 40% of...
10.
Schroter N, Jost W, Rijntjes M, Coenen V, Groppa S, Sajonz B
Fortschr Neurol Psychiatr
. 2024 Feb;
92(12):502-508.
PMID: 38346694
In the therapy of Parkinson̓s disease, both the intrajejunal administration of Levodopa/Carbidopa Intestinal Gel (LCIG) and, more recently, Levodopa/Carbidopa/Entacapone Intestinal Gel (LECIG), as well as deep brain stimulation (DBS), are...